Glucocorticoid-induced osteoporosis

Clinical and Experimental Rheumatology

Volumn 29, Issue 5 SUPPL. 68, 2011, Pages

  Den Uyl, D ^a   Bultink, I E M ^a   Lems, W F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone; Glucocorticoids; Osteoporosis

Indexed keywords

ALENDRONIC ACID; CALCIUM; CATHEPSIN K INHIBITOR; DENOSUMAB; GLUCOCORTICOID; IBANDRONIC ACID; NERIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISONE; RALOXIFENE; RISEDRONIC ACID; SCLEROSTIN; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

ARTICLE; BODY MASS; BONE METABOLISM; BONE STRENGTH; DRUG MEGADOSE; FRAGILITY FRACTURE; HUMAN; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR;

FRACTURES, BONE; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS; RISK FACTORS;

EID: 81155144639     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. KANIS JA, JOHANSSON H, ODEN A et al.: A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19: 893-9. (Pubitemid 41103445)
2. VOSSE D, DE VK: Osteoporosis in rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009; 27 (Suppl. 55): S62-S67.
3. VAN STAA TP, LEUFKENS HG, COOPER C: The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis. Osteoporos Int 2002; 13:777-87. (Pubitemid 36336722)
4. NATSUI K, TANAKA K, SUDA M et al.: High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int 2006; 17: 105-8. (Pubitemid 41798034)
5. REID DM, DEVOGELAER JP, SAAG K et al.: Zoledronic acid and risedronate in the prevention and treatment of glucocorticoidinduced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009; 373: 1253-63.
6. ADACHI JD, SAAG KG, DELMAS PD et al.: Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44: 202-11. (Pubitemid 32113136)
7. COOPER C, COUPLAND C, MITCHELL M: Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995; 54: 49-52.
8. VAN STAA TP, GEUSENS P, POLS HA, DE LC, LEUFKENS HG, COOPER C: A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 2005; 98: 191-8. (Pubitemid 40361316)
9. VAN STAA TP: The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006; 79: 129-37. (Pubitemid 44440440)
10. HOES JN, JACOBS JW, HULSMANS HM et al.: High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the alendronate or alfacalcidol in glucocorticoid-induced osteoporosistrial. Clin Exp Rheumatol 2010; 28): 354-9.
11. DE VRIES VF, BRACKE M, LEUFKENS HG, LAMMERS JW, COOPER C, VAN STAA TP: Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 2007;56:208-14. (Pubitemid 46106193)
12. KANIS JA, BORGSTROM F, DE LAET C et al.: Assessment of fracture risk. Osteoporos Int 2005; 16:581-9. (Pubitemid 40897454)
13. LEMS WF: Bisphosphonates and glucocorticoids: effects on bone quality. Arthritis Rheum 2007; 56: 3518-22. (Pubitemid 350100684)
14. VAN STAA TP, LEUFKENS HG, ABENHAIM L, BEGAUD B, ZHANG B, COOPER C: Use of oral corticosteroids in the United Kingdom. QJM 2000; 93: 105-11. (Pubitemid 30098773)
15. VAN STAA TP, LAAN RF, BARTON IP, COHEN S, REID DM, COOPER C: Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003; 48: 3224-9. (Pubitemid 37409336)
16. WEINSTEIN RS, JILKA RL, PARFITT AM, MANOLAGAS SC: Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998; 102: 274-82. (Pubitemid 28335186)
17. BRESSOT C, MEUNIER PJ, CHAPUY MC, LEJEUNE E, EDOUARD C, DARBY AJ: Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis. Metab Bone Dis & Rel Res 1979; 1:303-11.
18. O'BRIEN CA, JIA D, PLOTKIN LI et al.: Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004; 145: 1835-41. (Pubitemid 38402392)
19. LIU Y, PORTA A, PENG X et al.: Prevention of glucocorticoidinduced apoptosis in osteocytes and osteoblasts by calbindin-D28k. J Bone Miner Res 2004; 19: 479-90. (Pubitemid 38787404)
20. YUN SI, YOON HY, JEONG SY, CHUNG YS: Glucocorticoid induces apoptosis of osteoblast cells through the activation of glycogen synthase kinase 3beta. J Bone Miner Metab 2009; 27: 140-8.
21. OHNAKA K, TANABE M, KAWATE H, NAWATA H, TAKAYANAGI R: Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 2005; 329: 177-81. (Pubitemid 40255437)
22. WANG FS, KO JY, YEH DW, KE HC, WU HL: Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology 2008; 149: 1793-801.
23. PEREIRA RC, DELANY AM, CANALIS E: Effects of Cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone 2002; 30: 685-91. (Pubitemid 34467988)
24. SHI XM, BLAIR HC, YANG X, MCDONALD JM, CAO X: Tandem repeat of C/EBP binding sites mediates PPARgamma2 gene transcription in glucocorticoid-induced adipocyte differentiation. J Cell Biochem 2000; 76: 518-27. (Pubitemid 30078460)
25. CARCAMO-ORIVE I, GAZTELUMENDI A, DELGADO J et al.: Regulation of human bone marrow stromal cell proliferation and differentiation capacity by glucocorticoid receptor and AP-1 crosstalk. J Bone Miner Res 2010; 25:2115-25.
26. HOFBAUER LC, GORI F, RIGGS BL et al.: Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999; 140: 4382-9. (Pubitemid 30666099)
27. KONDO T, KITAZAWA R, YAMAGUCHI A, KITAZAWA S: Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels. J Cell Biochem 2008; 103: 335-45.
28. KIM HJ, ZHAO H, KITAURA H et al.: Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 2006; 116: 2152-60. (Pubitemid 44162324)
29. CANALIS E, MAZZIOTTI G, GIUSTINA A, BILEZIKIAN JP: Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007; 18: 1319-28. (Pubitemid 47389469)
30. GILLESPIE LD, ROBERTSON MC, GILLESPIE WJ et al.: Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2009; (2): CD007146.
31. LIPS P: Relative value of 25(OH)D and 1,25(OH)2D measurements. J Bone Miner Res 2001; 22: 1668-71.
32. TANG BM, ESLICK GD, NOWSON C, SMITH C, BENSOUSSAN A: Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007; 370: 657-66. (Pubitemid 47285316)
33. BLACK DM, COOPER C: Epidemiology of fractures and assessment of fracture risk. Clin Lab Med 2000; 20: 439-53. (Pubitemid 30655877)
34. KANIS JA, BURLET N, COOPER C et al.: European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008; 19: 399-428.
35. COHEN S, LEVY RM, KELLER M et al.: Risedronate therapy prevents corticosteroidinduced bone loss: a twelve-month, multi-center, randomized, double-blind, placebocontrolled, parallel-group study. Arthritis Rheum 1999;42:2309-18.
36. REID DM, HUGHES RA, LAAN RF et al.: Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-induced Osteoporosis Treatment Study. J Bone Miner Res 2000; 15: 1006-13. (Pubitemid 30350063)
37. WALLACH S, COHEN S, REID DM et al.: Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000; 67: 277-85.
38. SAAG KG, EMKEY R, SCHNITZER TJ et al.: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339: 292-9. (Pubitemid 28366417)
39. AMIN S, LAVALLEY MP, SIMMS RW, FELSON DT: The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 2002; 17: 1512-26. (Pubitemid 34803834)
40. FAHRLEITNER-PAMMER A, PISWANGERSOELKNER JC, PIEBER TR et al.: Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebocontrolled trial. J Bone Miner Res 2009; 24: 1335-44.
41. BENUCCI M, SAVIOLA G, BAIARDI P et al.: Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids. Clin Exp Rheumatol 2009; 27: 567-73.
42. MOK CC, YING KY, TO CH et al.: Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. Ann Rheum Dis 2011; 70: 778-84.
43. TEITELBAUM SL, SETON MP, SAAG KG: Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? Arthritis Rheum 2011; 63: 325-8.
44. SAAG KG, SHANE E, BOONEN S et al.: Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357: 2028-39. (Pubitemid 350106710)
45. SAAG KG, ZANCHETTA JR, DEVOGELAER JP et al.: Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009; 60: 3346-55.
46. LANGDAHL BL, RAJZBAUM G, JAKOB F et al.: Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 2009; 85: 484-93.
47. YAO W, CHENG Z, PHAM A et al.: Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum 2008; 58: 3485-97.
48. WEINSTEIN RS, JILKA RL, ALMEIDA M, ROBERSON PK, MANOLAGAS SC: Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice. Endocrinology 2010; 151:2641-9.
49. VAN BRUSSEL MS, BULTINK IE, LEMS WF: Prevention of glucocorticoid-induced osteoporosis. Expert Opin Pharmacother 2009; 10: 997-1005.
50. GROSSMAN JM, GORDON R, RANGANATH VK et al.: American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62: 1515-26.